Smithkline Beecham Corporation v. Abbott Laboratories

Good Law
United States Court of Appeals for the Ninth CircuitJune 24, 201411-17357California2,992 words

Opinion

Opinion

FOR PUBLICATION

UNITED STATES COURT OF APPEALS

FOR THE NINTH CIRCUIT

SMITHKLINE BEECHAM No. 11-17357

CORPORATION, DBA

GlaxoSmithKline, D.C. No. Plaintiff-Appellee, 4:07-cv-05702-CW

v.

ABBOTT LABORATORIES,

Defendant-Appellant.

SMITHKLINE BEECHAM No. 11-17373

CORPORATION, DBA

GlaxoSmithKline, D.C. No. Plaintiff-Appellant, 4:07-cv-05702-CW

v.

ORDER

ABBOTT LABORATORIES,

Defendant-Appellee.

Filed June 24, 2014

Before: Mary M. Schroeder, Stephen Reinhardt, and Marsha S. Berzon, Circuit Judges.

Order; Dissent by Judge O’Scannlain SUMMARY*

Equal Protection

The panel filed an order rejecting a sua sponte en banc call.

In its opinion filed January 21, 2014, the panel reversed the district court’s judgment in an antitrust case concerning a licensing agreement and the pricing of HIV medications. The panel held that classifications based on sexual orientation are subject to heightened scrutiny, and that in jury selection, equal protection prohibits peremptory strikes based on sexual orientation.

Dissenting from the denial of rehearing en banc,…

Sign in to read the full opinion

Create a free account to read the complete opinion text, citation history, and good-law status for this case.